Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, discusses the current treatment discontinuation rate of 20-25% among patients with CML. Dr Cortes also emphasized the need to continue working to identify strategies, including combination therapies, to decrease that rate.